What are you looking for?
The biosimilar aflibercept-ayyh was associated with stable vision in patients who switched from other anti-VEGF therapies and improved vision in treatment-naïve patients, according to a real-world analysis. The analysis included 1,000 consecutive eyes from 989 patients who received a total of 3,730 injections. Most eyes (91%) had previously been treated with another anti-VEGF therapy, while... ...
Switching to aflibercept 8 mg improved anatomical outcomes and reduced reliance on shorter treatment intervals, according to a study. However, researchers note...
Intravitreal aflibercept 8 mg administered with a loading phase followed by a treat-and-extend regimen improved visual acuity and reduced retinal and choroidal...
Patients with age-related macular degeneration (AMD) were found to have a higher risk of developing several mental health disorders, including depression, anxiety,...
Endophthalmitis remains a rare complication of intravitreal injections despite shifts in anti-VEGF treatment patterns, according to a study. Researchers conducted a retrospective case series of all patients who underwent intravitreal...
Deepak Sambhara, MD, FASRS, of the Eye Clinic of Wisconsin, talks about the unmet need in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), as well as emerging...
In the latest episode of The Ophthalmic Project, host Mark Dlugoss speaks with Michael O’Rourke, CEO of Re-Vana Therapeutics, about the company’s 2 biodegradable, photocrosslinked ocular drug delivery platforms: EyeLief... ...
Luke Yaldo, MA, of the University of Miami Miller School of Medicine, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about the link between obstructive sleep apnea (OSA)...
The U.S. Food and Drug Administration has approved extended dosing intervals for EYLEA HD (aflibercept), allowing treatment up to every 20 weeks in patients with wet age-related macular degeneration (wAMD)...
A post hoc subgroup analysis of the PULSAR trial found that baseline disease severity did not meaningfully affect clinical outcomes in treatment-naïve neovascular age-related macular degeneration (nAMD) treated with aflibercept... ...
Sterile intraocular inflammation (IOI) occurred more frequently with intravitreal aflibercept 8 mg in real-world use than previously reported in clinical trials, with significantly higher rates observed when injections were administered...
Switching to intravitreal aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration (nAMD) was associated with anatomical improvements and longer treatment intervals while visual acuity remained stable...